DDX3X与SIRT7相互作用,促进PD-L1的表达,以促进PDAC的进展
Tianming Zhao1,2,3, Hanlong Zhu4, Tianhui Zou5
1Department of Gastroenterology, Nanjing Drum Tower Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Jiangsu, Nanjing, 210008, China.
Oncogenesis
|February 5, 2024
概括
较高的DDX3X蛋白水平通过与SIRT7.7相互作用,促进胰腺癌 (PDAC) 的生长. 抑制这个DDX3X-SIRT7轴为PDAC患者提供了新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 胰腺管道腺癌 (PDAC) 是一种具有很低生存率的高度侵袭性癌症.
- 增加DDX3X表达与PDAC患者的预后不佳有关,但机制尚不清楚.
研究的目的:
- 研究DDX3X在PDAC进展中的作用背后的分子机制.
- 探索DDX3X与其他蛋白质的相互作用及其对PDAC发育的影响.
主要方法:
- 生物信息学分析,体外和体内研究.
- 分子技术包括西式涂抹,qPCR,免疫组织化学,免疫光学,质谱学,共免疫沉和多重免疫组织化学染色.
主要成果:
- 在PDAC组织中,DDX3X被显著上调.
- DDX3X knockdown 抑制了 PDAC 细胞的增殖,入侵和迁移,而过度表达则促进了这些.
- DDX3X与SIRT7相互作用,促进PDAC的进展;SIRT7抑制可以抵消DDX3X的影响.
- PD-L1表达与DDX3X水平正相关.
结论:
- DDX3X-SIRT7轴对PDAC启动和进展至关重要.
- 准DDX3X-SIRT7通路为PDAC提供了一个新的治疗策略.
- 在PDAC中,DDX3X可以作为预后生物标志物.
更多相关视频
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
442
11:06Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation
Published on: September 20, 2017
6.2K
相关概念视频
02:23Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
01:22PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K